Avir Green Hills Biotechnology Ag

AVIR Green Hills Biotechnology AG: deltaFLU - Innovative Vaccines for Intranasal Spray Delivery or Oral Administration

By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished yet Another Milestone in the Development of this Novel Influenza Vaccine. Completion of this Clinical Phase II Study is Envisaged for Spring 2010

VIENNA, November 7, 2011 - Innovative vaccines for intranasal spray delivery or oral administration combine high efficacy with easy application.

MORE..

Older News

VIENNA, Austria, January 14 - AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU.

MORE..